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Severe Systemic Calciphylaxis in a Young Cat
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A 7-month-old female intact domestic shorthair/British Blue crossbreed cat was referred to the
Queen Mother Hospital for Animals (QMHA) of the
Royal Veterinary College for further investigation of
progressive lethargy preceded by 48 hours of mixed
bowel diarrhea, moderate pyrexia (39.9°C; 103.8°F),
and unproductive retching. Laboratory tests performed
at the primary practice identified marked hypercalce-
mia (serum total calcium concentration). Despite treat-
ment with IV fluids and potentiated amoxicillin, the
cat deteriorated clinically, prompting referral. On pre-
sentation to the QMHA, the cat was dull but respon-
sive with poor body condition (3.5/9) and pyrexia
(39.2°C; 102.6°F). Firm white lingual plaques were
observed (Fig 1). Both kidneys were subjectively mildly
enlarged. The remainder of the physical examination
was unremarkable. With the exception of the cat’s
decreased mentation, neurologic examination was con-
sidered normal. No neurologic deficits suggesting a
structural intracranial lesion were found at any point
throughout the time the cat was hospitalized, but the
level of obtundation would wax and wane. No associa-
tion between the cat’s mentation and the treatments
administered was apparent.
Initial investigations confirmed marked total hyper-
calcemia (19.28 mg/dL; 4.82 mmol/L; reference inter-
val [RI], 8.28–10.72 mg/dL) and ionized hypercalcemia
(9.0 mg/dL; 2.25 mmol/L; RI, 4.52–5.32 mg/dL), with
mild hyperphosphatemia (7.68 mg/dL; 2.48 mmol/L;
RI, 2.85–6.69 mg/dL). Markedly increased serum CK
activity was identified (21,322 U/L; RI, 52–506 U/L)
increasing to 43,616 U/L upon repeated measurement
after 3 days. Serum ALT activity was within normal
limits. At the time of presentation, serum urea nitro-
gen concentration was moderately increased (49.0 mg/
dL; 17.5 mmol/L; RI, 17.1–33.6 mg/dL), whereas
serum creatinine concentration was within normal
limits (1.36 mg/dL; 118 lmol/L; RI, 0.84–2.1 mg/dL).
Interpretation of complete blood cell count was consis-
tent with a stress leukogram. Mild leukocytosis
(26.2 9 109/L; RI, 5.5–19.5 9 109/L) with mild neu-
trophilia (23.8 9 109/L; RI, 2.5–12.5 9 109/L) and
mild lymphopenia (0.58 9 109/L; RI, 1.5–7.0 9 109/L)
were present. Urinalysis disclosed the presence of gran-
ular casts (10 per 81 high-power fields, 4009), but was
otherwise unremarkable. Urine specific gravity was
1.015 (after IV fluid therapy).
Venous blood gas, electrolyte, and metabolite analy-
ses were performed throughout hospitalization to mon-
itor plasma creatinine, urea, and ionized calcium
concentrations. Plasma ionized calcium concentration
gradually decreased from 9.0 mg/dL to 7.44 mg/dL
24 hours after admission, whereas blood urea nitrogen
and creatinine concentration increased to 142.6 mg/dL
(50.9 mmol/L) and 3.0 mg/dL (268 lmol/L), respec-
tively. The azotemia was believed to be at least partly
prerenal, because it gradually resolved over the next
48 hours, with concurrent decreases in packed cell vol-
ume and total protein concentration (from 30% and
6.4 g/dL to 20% and 5.4 g/dL, respectively). During
the first 3 days of hospitalization, treatment included
IV fluid therapy (up to 8 mL/kg/h by the second day),
furosemidea (0.5–1.0 mg/kg IV q6h), and salmon calci-
toninb (4 IU/kg SC q8h), all of which were initiated
on the first day of hospitalization. Furosemide proba-
bly contributed to dehydration and development of
azotemia, supported by a 100 g (4.8%) decrease in
body weight over the first 24 hours. Owing to persis-
tent hypercalcemia despite treatment, IV pamidronatec
infusion (1.75 mg/kg diluted in 16 mL 0.9% NaCl,
infused at a rate of 4 mL/h) was administered on the
third day of hospitalization, at which time salmon
calcitonin was discontinued. These treatments failed to
substantially alter the plasma ionized calcium concen-
tration, but approximately 48 hours after initiating
prednisoloned treatment (0.5 mg/kg PO q12h) on day
6 of hospitalization, plasma ionized calcium con-
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centration was within normal limits (4.76 mg/dL;
1.19 mmol/L). Plasma ionized calcium concentration
subsequently increased to 6.04 mg/dL (1.51 mmol/L)
and remained at that concentration for the remainder
of hospitalization.
Thorough investigations did not identify an underly-
ing cause for the hypercalcemia. Plasma parathyroid
hormone (PTH)e concentration was 10 pg/ml (RI,
<40 pg/mL; sample obtained at the time of ionized
hypercalcemia), whereas plasma PTH-related protein
(PTHrP)f concentration was equivocally increased
(14.25 pg/mL; 1.5 pmol/L; RI, <9.5 pg/mL). Plasma
PTHrP concentrations >20.9 pg/mL are considered
suggestive of malignancy. Thoracic and abdominal
imaging identified only nonspecific changes consistent
with tissue mineralization, and neoplastic disease hence
was considered unlikely. Thoracic radiography dis-
closed a diffuse bronchial pattern with mild bronchial
mineralization. Abdominal radiography identified loss
of serosal detail, consistent with lack of intra-abdomi-
nal fat; both kidneys appeared slightly enlarged.
Abdominal ultrasound examination confirmed slight
bilateral renomegaly (both kidneys measuring 4 cm in
length), with hyperechoic speckled cortices and bilat-
eral medullary rim sign. Bilateral pyelectasia (1–2 mm)
was present, and attributed to IV fluid therapy. Fine-
needle aspirates of the kidneys obtained under ultra-
sound guidance to investigate the possibility of renal
lymphoma did not identify any lymphocytes or micro-
organisms. Because vitamin D toxicosis was a differen-
tial diagnosis for hypercalcemia in this patient (usually
associated with mildly increased serum inorganic
phosphorus concentration), plasma 25-hydroxyvitamin
D concentration was measured, yielding a value
of 22.8 ng/mL; 57 nmol/L (RI, 26.0–68.1 ng/mL).
Granulomatous diseases are thought to cause hypercal-
cemia through synthesis of vitamin D analogs,1 and
could have explained the increased serum CK activity
in this patient. However, a serum Toxoplasma gondii
microagglutination test, a serum cryptococcal latex
agglutination test, a feline coronavirus antibody titer,
and a Baermann flotation for feline lungworm (Aeluro-
strongylus spp.) all were negative. Serum cortisol con-
centration was 6.8 lg/dL (188.0 nmol/L), probably
ruling out glucocorticoid-deficient hypoadrenocorti-
cism as a cause of the hypercalcemia. Looking for
other explanations for the decreased and somewhat
waxing and waning mentation, the possibility of a por-
tosystemic vascular anomaly (PSVA) was explored.
Plasma ammonia concentration was moderately
increased (211 lg/dL; 124 lmol/L; RI, 0–102 lg/dL),
whereas serum concentrations of pre- and postprandial
bile acids were within normal limits, as were results of
biochemical liver function tests in combination with an
ultrasonographically normal appearance of the liver.
These results suggested that a PSVA was highly unli-
kely. The hyperammonemia was considered unlikely to
be of clinical relevance, because a direct association
with the more clinically relevant findings in this patient
(ie, marked hypercalcemia and widespread mineraliza-
tion) was not apparent.
The cat’s mentation did not change substantially
despite transient normalization of the plasma ionized
calcium concentration. In light of the poor quality of
life and poor prognosis, the owner elected euthanasia.
Postmortem examination confirmed calcification of the
lungs, kidneys, major blood vessels, and skeletal mus-
cles, the latter in combination with marked dystrophic
lesions.
The most prominent features of the histopathologic
examination were multifocal metastatic calcifications
affecting multiple tissues, and multifocal degenerative
myopathy (Fig 2). Several sections of skeletal muscle
had multifocal myofiber atrophy, degeneration, and
calcification with interstitial fibroplasia. Foci of ische-
mic necrosis affecting whole muscle fascicles occasion-
ally were noted (eg, triceps brachii), demonstrating
swelling and hypereosinophilia of affected myofibers.
Multinucleated regenerative myofibers were inter-
spersed with atrophic, degenerate, and calcified fibers.
Lakes of calcified debris forming nodules at the lingual
margins were present, as was multifocal gastric mucosal
calcification. Radial cortical calcification, centered on
tubular basement membranes, was demonstrated in the
kidneys, providing an explanation for the granular
casts. Multifocal basement membrane calcification of
small airways and blood vessels also was observed, and
the adrenal glands had focal calcification. Representa-
tive sections of the brain (cerebrum and medulla oblon-
gata), spinal cord (with spinal nerve and dorsal root
ganglion), and pituitary gland were microscopically
normal, whereas parathyroid tissue was atrophic.
In light of the multiple muscle fiber abnormalities
and markedly increased serum CK activity, a form of
muscular dystrophy was considered as a differential
diagnosis in this cat once a number of more common
granulomatous diseases had been eliminated, but the
Fig 1. Firm white lingual plaques observed at the time of
presentation.
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hypercalcemia was considered unusual for a primary
muscular dystrophy. Samples of quadriceps and triceps
muscles were obtained immediately postmortem and
snap-frozen in isopentane, cooled in liquid nitrogen.
An extended staining panel conducted on 8 lm
cryosections included hematoxylin and eosin, periodic
acid Schiff, modified Gomori trichrome, oil red O, and
Alizarin red (Fig 2). There were prominent dystrophic
features within the triceps and quadriceps muscles,
consisting of marked fiber size variation, numerous
internalized nuclei, basophilic regenerating fibers,
increased endomysial and perimysial connective tissue,
Fig 2. Staining panel performed on triceps and quadriceps biopsy fresh-frozen muscle sections. Note widespread dystrophic calcification
and degeneration with islands of regenerating (basophilic) fibers, internalized nuclei, and infiltrating mononuclear cells (hematoxylin and
eosin [H&E] and Gomori trichrome stains). Periodic acid Schiff stain identified small amounts of fine granular glycogen in most fibers,
with some fibers devoid of glycogen. Alizarin red stain identified deposits of calcium salts in the walls of blood vessels, in the endomy-
sium and within a few muscle fibers. Oil red O stain identified accumulation of lipid droplets (red specks) in the cytoplasm of some
fibers. Scale bars = 100 lm.
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and large areas of infiltrating mononuclear cells
(probably macrophages). The Alizarin red stain con-
firmed the presence of prominent accumulations of
calcium in sarcoplasmic and extracellular regions, and
there also was a marked accumulation of calcium
deposits in the smooth muscle of blood vessels. Oil
red O stain identified fine punctate lipid accumulation
in many fibers.
Extensive diagnostic evaluation failed to disclose a
definitive diagnosis for this cat. Neither of the
described muscular dystrophies was considered to fit
the clinical or histopathologic picture. The cat was
female, hence X-linked dystrophin deficiency would be
highly unlikely,2 and the cat did not display the typical
extensor contracture of the pelvic limbs or lipid accu-
mulation in the muscle fibers seen with laminin a2
(merosin) deficiency,2 nor the ventroflexed neck and
dorsally protruding scapulae described in a-dystrogly-
can deficiency; moreover, the latter cases had normal
CK activity.3 Of the muscular dystrophies described in
companion animals, b-sarcoglycan deficiency initially
was considered a possibility in this cat. This condition
has been associated with hypercalcemia in a domestic
shorthair cat and a Boston Terrier, associated in both
cases with markedly increased serum CK activity, but
these patients had mild total hypercalcemia attributed
to young age.4,5 In light of the absence of muscle fiber
hypertrophy, the marked hypercalcemia, and the wide-
spread calcium deposition in other organs and blood
vessels in our patient, we considered the dystrophic
features of the muscle fibers likely to be an effect
rather than a primary cause of the disease.
No underlying cause for this patient’s hypercalcemia
was identified, rendering idiopathic hypercalcemia our
presumptive diagnosis. Although serum PTHrP concen-
tration was mildly increased, no evidence of neoplasia
was found on postmortem examination. Despite the
detectable plasma PTH concentration, primary hyper-
parathyroidism was ruled out on the basis of the atro-
phic parathyroid glands. Furthermore, this is a rare
condition in cats, usually presenting in older animals
and associated with a low-normal to decreased serum
phosphate concentration.6 Although increased concen-
trations of plasma ionized calcium, PTH, and phos-
phate would be expected in so-called ‘tertiary
hyperparathyroidism’, this condition has only been
described infrequently in cats with advanced renal dis-
ease (IRIS stages 3–4), after a period of renal secondary
hyperparathyroidism.7 This was not consistent with the
mild, transient azotemia in this patient, and would have
resulted in hyperplasia of the parathyroid glands.
Although idiopathic hypercalcemia is relatively com-
mon in cats, reportedly accounting for an increasing
proportion of hypercalcemia in this species,8 severe
metastatic calcification has hitherto not been described
in these patients. Serum phosphate concentration was
above the RI in this patient, resulting in a markedly
increased Ca 9 P product. Young animals normally
have higher calcium or phosphate concentrations or
both than adults and are thought to be more resistant
to tissue mineralization.9 However, the magnitude of
the electrolyte derangements in this patient accounted
for the severe, widespread mineralization.
Calciphylaxis is a term that was first used by Seyle
to describe a ‘systemic hypersensitivity’ resulting in
systemic calcification in animals that were sensitized by
so-called ‘calcifiers’ (eg, vitamin D analogs, PTH) and
subsequently exposed to a ‘challenger’ (eg, iron, alumi-
num, trauma).10 In humans, a similar syndrome of cal-
ciphylaxis or systemic calcinosis also is called calcific
uremic arteriolopathy, and is a rare condition usually
seen in patients with end-stage renal disease and in
renal transplant patients.11,12 Although incompletely
understood, consequences of their disease such as
hyperphosphatemia and tertiary hyperparathyroidism
are thought to play a role.11,12 In companion animals,
systemic calcification has been described in patients
with vitamin D intoxication resulting in hypercalcemia
and hyperphosphatemia, as well as renal disease.13–16
The calcification in these human and veterinary
patients has occurred primarily within the intima of
blood vessel walls, resulting in ischemia and necrosis
with subsequent mineralization.11–15 In our patient,
subintimal calcification was noted in larger blood ves-
sels as well as in blood vessels in the musculature,
including the myocardium, with associated ischemia,
necrosis, and calcification. However, calcium deposits
also were demonstrated within the myoplasma (best
visualized with the Alizarin red stain, Fig 2). This
pathology is unusual in humans, and when present
usually is preceded by calcification of the skin.12,17 To
our knowledge, extensive calcification of the striated
musculature has not been demonstrated previously in
either cats or dogs without preexisting muscular dis-
ease,13–15,18,19 but a recent case series described sys-
temic calcification in 5 horses, all of which exhibited
muscle calcification and increased serum CK activi-
ties.20 The reason for calcification in these patients was
unclear, but the authors speculated that they were
‘sensitized’ by an increased Ca 9 P product (2 horses)
or hyperphosphatemia (5 horses), and subsequently
challenged by steroids, plasma administration, trauma,
an inflammatory condition, or some combination of
these factors, resulting in systemic calcification. Inter-
estingly, all of these horses had decreased (2 horses) or
normal (3 horses) calcium concentrations, and only 2
had an increased Ca 9 P product. A recent report
described idiopathic calciphylaxis in a 10-week-old
male domestic shorthair kitten,21 but this kitten dif-
fered from our patient by predominantly presenting
for severe cutaneous lesions and experiencing full
recovery with symptomatic treatment. Furthermore,
apart from assumed age-related hyperphosphatemia,
the kitten’s laboratory test results were unremarkable,
including a normal Ca 9 P product. The cutaneous
calcification was hypothesized to represent an inherited
disorder. Unlike our patient, this kitten did not have
any apparent reason for generalized mineralization,
possibly explaining why the calcification was limited to
the skin. Our patient suffered from systemic calcifica-
tion involving muscle and visceral organs, presump-
tively a consequence of the markedly increased
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Ca 9 P product. The potentially deleterious conse-
quences of an increased Ca 9 P product emphasize
the importance of monitoring the Ca 9 P product in
hypercalcemic patients, and suggest that every effort
should be made to decrease it (and thereby probably
the risk of mineralization) as soon as possible.
This report describes, to our knowledge, the first
documentation of severe systemic calciphylaxis with
hypercalcemia in a cat. On the basis of the clinical pre-
sentation and thorough ante- and postmortem investi-
gations, we conclude that the markedly increased
Ca 9 P product in this patient accounted for the min-
eralization, with the extensive muscle fiber calcification
explaining the markedly increased serum CK activity.
We consider the patient’s decreased mentation to be a
result of the systemic effects of the severe tissue miner-
alization, which did not resolve within a matter of
days15,22 despite transient normocalcemia. Pain is one
of the initial signs of calciphylaxis in humans,23 and
the cat may have responded to painful sensation with
decreased mentation, although the cat did not appear
painful when handled. The hypercalcemia itself also
may have contributed to this patient’s decreased men-
tation. Human patients with hypercalcemia related to
primary hyperparathyroidism can present with head-
aches, fatigue, nausea, and mental disturbances,
including coma.24 These signs have been found to cor-
relate with the degree of hypercalcemia rather than
plasma PTH concentration, with clinical improvement
corresponding to decreasing calcium concentration
despite persistently high PTH concentration.24 The
lack of clinical improvement in our patient at the time
of normocalcemia, however, does not support hyper-
calcemia as the sole cause of obtundation. Hyperam-
monemia contributing to the patient’s decreased
mentation was considered unlikely, but could not be
eliminated. Because mammalian muscle produces
ammonia,25 muscle necrosis may have caused the
hyperammonemia in this patient.
Footnotes
a Furosemide monoethanolamine (Dimazon, injectable, 5% w/v
Furosemide monoethanolamine; per 1 mL: 50 mg Furosemide
monoethanolamine, 15 mg benzyl alcohol, 1 mg Disodium Ede-
tate Dihydrate, and 1.8 mg sodium Sulphite Anhydrous), Inter-
vet UK Ltd, Walton Manor, Milton Keynes, Bucks, MK7 7AJ,
UK
b Calcitonin Salmon (Miacalcic, injectable, 100 IU/mL), Sandoz
Pharmaceuticals, Frimley Business Park, Camberley, Surrey,
GU16 7SR, UK
c Pamidronate disodium pentahydrate (Aredia, 15 mg/5 mL),
Ciba Laboratories, Frimley Business Park, Camberley, Surrey,
GU16 7SR, UK
d Prednisolone (Prednicare tablets, 1 mg), Animal Care ltd, York,
YO19 5RU, UK
e Enzyme-linked immunosorbent assay, IDS limited, Cambridge
Specialist Laboratories, UK. Canine PTH assay validated for
felines by parallelism (unpublished results, personal communica-
tion)
f Radioimmunoassay, Beckman Coulter, Cambridge Specialist
Laboratories, UK. Human PTHrP assay validated for felines by
the laboratory (unpublished results, personal communication)
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